Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and females, ≥18 to ≤77 years old, with type 2 diabetes mellitus~* Subjects must have central laboratory pre-randomization A1C ≥7.0 and ≤ 10.0%~* C-peptide ≥ 1.0 ng/mL (0.34 nmol/L)~* Body Mass Index ≤ 45 kg/m²~* Must be able to perform self monitoring of blood glucose~Exclusion Criteria:~* aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \>3\* upper limit of normal (ULN)~* Serum Total bilirubin \>2 mg/dL (34.2 µmol/L)~* Creatinine kinase \>3\* ULN~* Serum creatinine ≥1.50 mg/dL (133 µmol/L) for male subjects, ≥1.40 mg/dL (124 µmol/L) for female subjects~* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin 1 mg (Type: EXPERIMENTAL): Dapagliflozin: 1 mg
- Dapagliflozin 2.5 mg (Type: EXPERIMENTAL): Dapagliflozin: 2.5 mg
- Dapagliflozin 5 mg (Type: EXPERIMENTAL): Dapagliflozin: 5 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: 0 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).